We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.
- Authors
Hansma, A H G; Broxterman, H J; van der Horst, I; Yuana, Y; Boven, E; Giaccone, G; Pinedo, H M; Hoekman, K
- Abstract
Endostatin is an endogenous collagen XVIII-fragment with anti-angiogenic properties and remarkable antitumor activity in mice. Preclinical data suggest that continuous low dose administration of endostatin is much more potent than intermittent dosing. The feasibility of this approach is tested in a phase I study.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Vol 16, Issue 10, p1695
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdi318